Retroviruses and Other Viruses

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 746-759

  Barbara, John A J ^a,b   Dow, Brian C ^c  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882240172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch47     Document Type: Chapter

References (91)

1. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pantroglodytes troglodytes. Nature 1999;397:436-41.
2. Sharp PM, Bailes E, Chaudhuri RR, et al. The origins of acquired immune deficiency syndrome viruses: Where and when? On theorigin and evolution of the human immunodeficiency virus (HIV) and significance of HIV-1 genetic subtypes. Philos Trans R Soc Lond B Biol Sci 2001;356:867-76.
3. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006;78(Suppl 1): S7-12.
4. Janssens W, Buve A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS 1997;11:705-12.
5. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in central Africa. J Virol 2000;74:10498-507.
6. Weiss RA, Dagleish AG, Loveday, Human immunodeficiency viruses. In: Zuckerman AJ, Banatvala JE, Pattison, eds. Principles and practice of clinical virology, 4th ed. Chichester, UK: Wiley and Sons, 2000:659-94.
7. Lee CA. The natural history of HIV disease in haemophilia. Blood Rev 1998;12:135-44.
8. Schochetman G, Kuhns MC. HIV variants and hepatitis B surface antigen mutants: Diagnostic challenges for immunoassays. J Med Virol 2006;78(Suppl 1):S3-6.
9. Fiebig EW, Murphy EL, Busch MP. Human immunodeficiency virus, human T-cell lymphotrophic viruses, and other retroviruses. In: Hillyer CD, Silberstein LE, Ness PM, et al, eds. Blood banking and transfusion medicine: Basic principles and practice. Philadelphia, PA: Churchill Livingstone, 2003:447-64.
10. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005;353:1702-10.
11. Sepkowitz KA. One disease, two epidemics-AIDS at 25. N Engl J Med 2006;354:2411-14.
12. Merson MH. The HIV-AIDS pandemic at 25-the global response. N Engl J Med 2006;354:2414-17.
13. Geleziunas R, Greene WC, Molecular insights into HIV-1 infection and pathogenesis. In: Sande MA, Volberding PA, eds. The medical management of AIDS, 6th ed. Philadelphia, PA: WB Saunders, 1999:23-40.
14. Laperche S, Pillonel J. Influence of epidemiological factors on blood transfusion. ISBT Science Series 2007;2:78-84.
15. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Eurosurveillance 2005;10:17-19.
16. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiological Donor Study (REDS). JAMA 2000;284:229-35.
17. Dow BC. Microbiology confirmatory tests for blood donors. Blood Rev 1999;13:91-104.
18. Barbara J, Ramskill S, Perry K, et al. The National Blood Service (England) approach to evaluation of test kits for detecting infection. Transfus Med Rev 2007;21:147-58.
19. Ferguson M, Holmes H, Sands D. NIBSC/UK Blood Transfusion Service working standards for HBsAg, anti-HCV and anti-HIV 1 ('go/no-go' controls). Vox Sang 2001;80:205-10.
20. Nightingale MJ, Ramskill S, Newham J, et al. The systematic monitoring of transfusion microbiology test kit performance. Transfus Med 2007;17:404-12.
21. Stramer SL. Current risks of transfusion-transmitted agents. A review. Arch Pathol Lab Med 2007;131:702-7.
22. Ferreira MC, Nel TJ. Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion 2006;46:156-7.
23. Mitchell R, Dow BC, Barr A, et al. False positive anti-HIV tests on blood donations. Lancet 1988;332:297-8.
24. Jackson JB, Hanson MR, Johnson GM, et al. Long-term follow-up of blood donors with indeterminate human immunodeficiency virus type 1 results on Western blot. Transfusion 1995;35:98-102.
25. Sayre KR, Dodd RY, Tegtmeier G, etal. False-positive human immunodeficiency virus type 1 Western-blot tests in noninfected blood donors. Transfusion 1996;36:45-52.
26. Janssen RS, Aberle-Grasse J, Rawal BD, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8.
27. Busch MP, Aberle-Grasse J, Rawal BD, et al. Demographic correlates of HIV incidence among first-time blood donors (abstract). Transfusion 1998;38(Suppl):81S.
28. Adler MW. ABC of AIDS: Development of the epidemic. Br Med J 2001;322:1226-9.
29. Busch MP, Operskalski EA, Mosley JW, et al for the Transfusion Safety Study Group. Factors influencing HIV-1 transmission by blood transfusion. J Infect Dis 1996;174:26-33.
30. Crawford RJ, Mitchell R, Burnett AK, et al. Who may give blood? Br Med J (Clin Res Ed) 1987;294:572.
31. Busch MP, Stramer SL. The efficiency of HIV p24 antigen screening of US blood donors: Projections versus reality. Infusionstherapie Transfusionsmedizin 1998:25:194-7.
32. Busch MP. Transfusion-transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006;46:1624-40.
33. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viraemia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-9.
34. Delwart EL, Kalmin ND, Jones TS, et al. First case of HIV transmission by an RNA-screened blood donation. Vox Sang 2004;86:171-7.
35. Simon F, Loussert-Ajaka I, Damond F, et al. HIV type 1 diversity in northern Paris, France. AIDS Res Hum Retrovir 1996;12:1427-33.
36. Parry JV, Murphy G, Barlow KL, et al. National surveillance of HIV- 1 subtypes for England and Wales: Design, methods, and initial findings. J Acquir Immune Defic Syndr 2001;26:381-8.
37. Fleury H, Recordon-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: Molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retrovir 2003;19:41-7.
38. Delwart EL, Orton S, Parekh B, et al. Two per cent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retrovir 2003;19:1065-70.
39. Delwart E, Kuhns MC, Busch MP. Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: Implications for blood safety, diagnostics, treatment, and molecular epidemiology. J Med Virol 2006;78(Suppl 1):S30-35.
40. Wendel S. Rational testing for transmissible diseases. ISBT Science Series 2007;2:19-24.
41. Busch MP, Operskalski EA, Mosley JW, et al for the Transfusion Safety Study Group. Epidemiological background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion 1994;34:858-64.
42. Kleinman SH, Niland JC, Azen SP, et al. Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion 1989;29:572-80.
43. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibodypositive blood donations. Ann Intern Med 1990;113:733-9.
44. Busch MP, Donegan E, Stuart M, et al. Donor HIV-1 p24 antigenae- mia and course of infection in recipients. Transfusion Safety Study Group (letter). Lancet 1990;335:1342.
45. Rawal BD, Busch MP, Endow R, et al. Reduction of human immunodeficiency virus-infected cells from donor blood by leukocyte filtration. Transfusion 1989;29:460-2.
46. Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: Relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995;172:648-55.
47. Blaxhult A, Granath F, Lidman K, et al. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990;4:125-9.
48. Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999;340:1715-22.
49. Busch MP, Collier A, Gernsheimer T, et al. The Viral Activation Transfusion Study (VATS): Rationale, objectives, and design overview. Transfusion 1996;36:854-9.
50. Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: Implications for transfusion support of infected patients. Blood 1992;80:2128-35.
51. Collier A, Kalish L, Busch M, et al. Double-blind, randomized study of leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: Results of the Viral Activation Transfusion Study. JAMA 2001;285:1592-601.
52. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415-19.
53. Blattner W. Human retrovirology: HTLV. New York: Raven Press, 1990.
54. Brennan M, Runganga J, Barbara JAJ, et al. Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donations in north London. Br Med J 1993;307:1235-9.
55. Flanagan P, McAlpine L, Ramskill SJ, et al. Evaluation of a combined HIV 1/2 and HTLV-I/II assay for screening blood donors. Vox Sang 1995;68:220-4.
56. Dow BC, Munro H, Ferguson K, et al. HTLV antibody screening using mini-pools. Transfus Med 2001;11:419-22.
57. Davidson F, Lycett C, Jarvis LM, et al. Detection of HTLV-I and -II in Scottish blood donor samples and archive donations. Vox Sang 2006;91:231-6.
58. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
59. O'Brien SF, Yi Q-L, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007;47:316-5.
60. Peeters M, Courgnaud V, Abela B, et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis 2002;8:451-7.
61. Wolfe ND, Switzer WM, Carr JK, et al. Naturally acquired simian retrovirus infections in central African hunters. Lancet 2004;363:932-7.
62. Franklin IM, Dow BC, Jordan AD. Benefits of a blood donation archive repository: International survey of donor repository procedures and Scottish experiences. Transfusion 2007;47:1172-9.
63. Chang Y, Cesraman E, Pessin MS, et al. Identification of herpesviruslike DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
64. Allain JP. Emerging viral infections relevant to transfusion medicine. Blood Rev 2000;14:173-81.
65. Hecker M. Qiu D, Marquardt K, et al. Continuous cytomegalovirus seroconversion in a large group of healthy donors. Vox Sang 2004;86:41-4.
66. Franklin IM. Is there a right to donate blood? Patient rights; donor responsibilities. Transfus Med 2007;17:161-8.
67. Mach M, Stamminger R, Jahn G. Human cytomegalovirus: Recent aspects from molecular biology. J Gen Virol 1989;70:3117-46.
68. Pellett PE, Wright DJ, Engels EA, et al. Multicenter comparison of serological assays and estimations of human herpesvirus 8 seroprev- alence among US blood donors. Transfusion 2003;43:1260-8.
69. Preiksaitis JK. The cytomegalovirus-"safe" blood product: Is leu- koreduction equivalent to antibody screening? Transfus Med Rev 2000;14:112-36.
70. Blajchman MA, Goldman M, Freedman JJ, et al. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leucoreduction. Transfus Med Rev 2001;15:1-20.
71. Vamvakas E. Is white-blood-cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion: A review of the literature and meta-analysis. Transfus Med Rev 2005;19:181-99.
72. Dollard SC, Nelson KE, Ness PM, et al. Possible transmission of human herpesvirus-8 by blood transfsuion in a historical United States cohort, Transfusion 2005;45:500-3.
73. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006;355:1331-8.
74. Prowse C, Ludlam A, Yap P Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
75. Manaresi E, Gallinella S, Venturoli S, et al. Detection of parvovirus B19 IgG: Choice of antigens and serological tests. J Clin Virol 2004;29:51-3.
76. Candotti D, Etiz N, Parysan A, et al. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virology 2004;78:12169-78.
77. Lefrere JJ, Servant-Delmas A, Candotti D, et al. Persistent B19 infection in immunocompetent individuals: Implications for transfusion safety. Blood 2005;106:2890-5.
78. Heegard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
79. Prowse C, Dow B, Pelly SJ, et al. Human parvovirus B19 infection in persons with haemophilia (letter). Thromb Haemost 1998;80:351.
80. Fryer JF, Delwart E, Hecht FM, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007;47:1054-61.
81. Prowse CV. An ABC of West Nile virus. Transfus Med 2003;13:1-7.
82. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006;46:272-7.
83. Vamvakas EC, Kleinman S, Hume H, et al. The development of West Nile virus safety policies by Canadian Blood services: Guiding principles and a comparison between Canada and the United States. Transfus Med Rev 2006;20:97-109.
84. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003-2005. Transfusion 2006:46:2038-46.
85. Stramer SL, Custer B, Busch MP, et al. Strategies for testing blood donors for West Nile virus. Transfusion 2006;46:2036-7.
86. Charrel RN, de Lamballerie X, Durand JP, et al. Prevalence of antibody against West Nile virus in volunteer blood donors living in southeastern France. Transfusion 2001;41:1320-1.
87. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza (H5N1) virus infection in humans. N Engl J Med 2008;358:261-73.
88. Likos AM, Kelvin DJ, Cameron CM, et al. Influenza viremia and the potential for blood-borne transmission. Transfusion 2007;47:1080-8.
89. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006;354:2235-49.
90. de Lamballerie X, Fulhorst CF, Charrel RN. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 2007;47:172-3.
91. Simmonds P. Transfusion virology: Progress and challenges. Blood Rev 1998;12:171-7.